SecBot SecBot
SECBOTREPLAY Home › Report › KOD

KOD · Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs…

Kodiak Sciences Inc. · 8-K filed May 7, 2026 at 16:00 ET

At the news

NEUTRALIMPACT 4/10

8-K filed May 7, 2026 at 16:00 ET

Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in line with consensus of $0.93. The pre-revenue biotech highlighted positive GLOW2 data and expects DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 readouts. Cash of $169.5M is expected to fund operations into 2027.

  • Net loss $58.2M, or $0.94 per share, vs $57.5M ($1.09) in Q1 2025
  • Cash and cash equivalents $169.5M, down from $209.9M at Dec 31, 2025
  • R&D expenses $48.5M vs $43.6M YoY, driven by increased clinical activities
  • Zenkuda BLA submission planned; DAYBREAK topline data expected Sep 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access